LBI-HTA - Publications - Search - Wearable cardioverter-defibrillator (WCD) therapy in primary and secondary prevention of sudden cardiac arrest in patients at risk

Ettinger, S. and Stanak, M. and Huić, M. and Hacek, R.T. and Ercevic, D. and Grenkovic, R. and Wild, C. (2016): Wearable cardioverter-defibrillator (WCD) therapy in primary and secondary prevention of sudden cardiac arrest in patients at risk. Decision Support Document 103.

[img]PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
3197Kb
Abstract

Sudden cardiac arrest (SCA) is the most common cause of death in patients with coronary artery disease. In Europe, there are about 350 000 out of hospital SCAs per year. Mostly, ventricular tachycardia and ventricular fibrillation are the underlying aetiology of SCA, which is claimed to be successfully treated by a novel defibrillation therapy, a wearable cardioverter defibrillator (WCD).

This assessment, performed within the "European Network for Health Technology Assessment (EUnetHTA) Joint Action 3, aimed to provide valid data on clinical effectiveness and safety of the WCD. Furthermore, the project intended to elicit patients’ views on aspects regarding their cardiac disease and the WCD therapy as well as to identify neglected outcomes.

According to the published data, no statement can be made about the device's effectiveness – further research is needed. Studies suggest that the WCD could be a relatively safe intervention in the short to medium term. However, more data and more adequate reporting of (serious) adverse events are needed in order to establish the device safety. In particular, more data is needed for specific risk stratification of high risk patients in order to further narrow down the wide range of indications for WCD use.

Item Type:Decision Support Document
Keywords:Sudden cardiac arrest, ventricular tachycardia, ventricular fibrillation, (cardioverter-) defibrillator (external, wearable), countershock
Subjects:WB Practice of medicine > WB 300-962 Therapeutics
WG Cardiovascular system
Language:English
Series Name:Decision Support Document 103
Deposited on:15 Dec 2016 16:47
Last Modified:15 Dec 2016 16:47

Repository Staff Only: item control page